Thrilled to start 1/2026 as Chief of CV Medicine and Co-Director of the CV Institute @IUMedSchool / @IU_Health! Grateful for lifelong friends, colleagues, trainees @ NUFSM & continuing collabs. Excited for what's to come at IUSM/IUH! @IUSMDeptMed @saraj_pereira @IUCVInstitute

ANOTHER round of Top Site-Coordinators who have proven their dedication to the CV ecosystem through their impressive work in HF trials. Join us in congratulating all of our Site-Based Research award winners! 🎉 #AHA #AHA24 https://t.co/I9rjdFacjn

@MattFeinsteinMD joins us from @NUFeinbergMed @NMCardioVasc to discuss the complex immune system modifiers of cardiovascular disease. Wow. My head is spinning. So much to discuss with him today! @NMHheartdoc @HFpEF @WilcoxHeart @HeartDocSadiya have compelling reasons to be

In this #JACCBTS analysis, a common missense variant of ICAM-1 among African American individuals that has been associated with #HFpEF appears to be associated with circulating inflammatory proteins. Get the details: https://t.co/2wJNcHVeYi

In a large cohort of African-American women, the ICAM1 missense variant rs5491 (p.Lys56Met) was specifically associated with #HFpEF hospitalization among individuals starting at the age of 70 years. https://t.co/wMb3QdVPFj #JACCHF #HeartFailure #cvGenetics

REBALANCE-HF trial: While splanchnic ablation for volume management (SAVM) did not reduce PCWP in HFpEF overall, subgroup analysis suggests benefits in patients with preserved cardiac output during exercise and less severe diastolic dysfunction. https://t.co/u5GeuDz0tq

Mavacamten was associated with reductions in biomarkers of cardiac wall stress and injury, with no sustained reductions in LVEF observed in patients with HFpEF and LVEF of 60% or greater. https://t.co/Uct8nPrC4a #HFSA2024

Immune cell profiling of the ICAM1 p.K56M heart failure with preserved ejection fraction risk variant - PubMed

Feinberg investigators have been selected to lead a $15 million @American_Heart research initiative studying the role of #inflammation in #HeartDisease.

Over 2 years of follow-up, atrial shunting in patients with HFpEF and HFmrEF led to reverse remodeling of left-sided chambers and increases in volume of right-sided chambers but no change in RV systolic function compared with sham. https://t.co/qtdBf3VumJ

Amazing job by our fellow presenters and faculty moderators this morning recapping top line results from @ACCinTouch! @RBPatelMD @ALewisMD @NMCardioVasc @M_Leya27

Cardiology Grand Rounds @NMCardioVasc - recap #LBCT #ACC2024 - outstanding fellow led discussions. Will practice change? New hypotheses? PLUS 2 announcements: @jessquagginsmi1 - Bonow research proposal award winner & @WeAreNUHeart won @American_Heart fellow research award grant👏🏽

On Day 1 at #ACC24, Northwestern Medicine Bluhm Cardiovascular Institute resident, Kasen Culler, MD (@CullerKasen), presents his poster on the effect of #MetabolomicProfiling on #MyoInositol #metabolism in early #HeartFailure.

Please help us congratulate Mercedes Carnethon, PhD (@MCarnethon), who has been named the chair of the Department of Preventive Medicine! 👏 https://t.co/yavyyO81Ih

What's the mechanism by which cellular adhesion molecules are associated with #AFib and HFpEF? Read insights from the Multi‐Ethnic Study of Atherosclerosis (MESA) about VCAM-1 and ICAM-1. #AHAJournals @GrahamPeigh @RBPatelMD @NMCardioVasc https://t.co/7osvnim9s5

More than 6 million people in the U.S. have heart failure, making it one of the leading causes of hospitalization in the country. @NUFeinbergMed Prof. Sanjiv Shah (@HFpEF) explains how his team uses AI in diagnosis, and how it can improve health care: https://t.co/mDK8wBvuNB

Now out in @JAMANetworkOpen , @artschuermans and I w/ Alex Reiner @fredhutch examine the role of clonal hematopoiesis of indeterminate potential (CHIP) 🩸🧬 in future/incident development of heart failure and its subtypes (HFpEF and HFrEF) https://t.co/fgcEzzDH2A 👇 (1/X)

@NiruKrishMD @MaryWhooley @schopfermd @Aziz_Nagar @FrannyBartoli @AikawaElena @mandyturner_ @toleafgirl From LaPenna et al: Combination Sodium Nitrite and Hydralazine Therapy Attenuates Heart Failure With Preserved Ejection Fraction Severity in a “2‐Hit” Murine Model @kyle_lapenna @andrewlizhen @Sharp_Lab @RBPatelMD @HFpEF https://t.co/8KCIYxaKrm

We are elated! See this spectacular class of future cardiologists & scientists @NMCardioVasc @WeAreNUHeart @NUFeinbergMed @NorthwesternMed - to all newly matched cardiology fellows across the U.S., welcome to our community. You inspire us. Find your niche; #MakeADifference 👏🏽👏🏽👏🏽

As you follow along and retweet tonight, don’t forget to use the tag #CardsJC ‼️ And if you didn’t have time to read the article, check out our visual abstract as we get started